Transduced Tat-annexin protein suppresses inflammation-associated gene expression in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells

BMB Reports

Volumn 44, Issue 7, 2011, Pages 484-489

  Lee, Sun Hwa ^a   Kim, Dae Won ^a   Back, Su Sun ^a   Hwang, Hyun Sook ^a   Park, Eun Young ^a   Kang, Tae Cheon ^a   Kwon, Oh Shin ^b   Park, Jong Hoon ^c   Cho, Sung Woo ^d   Han, Kyu Hyung ^a   Park, Jinseu ^a   Eum, Won Sik ^a   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Kyungpook National University   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Cytokine; Inflammation; MAPK; Protein therapy; Tat ANX1

Indexed keywords

ANNEXIN; CYCLOOXYGENASE 2; CYTOKINE; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; PTGS2 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MOUSE;

ANIMALS; ANNEXINS; CELL LINE; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

MURINAE;

EID: 79961035071     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2011.44.7.484     Document Type: Article

References (39)

1. Bertolini, A., Ottani, A. and Sandrini, M. (2002) Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr. Med. Chem. 9, 1033-1043.
2. Korhonen, R., Lathi, A., Kankaanranta, H. and Moilanen, E. (2005) Nitric oxide production and signaling in inflammation. Curr. Drug Targets Inflamm. Allergy 4, 471-479.
3. Libby, P., Ridker, P. M. and Maseri, A. (2000) Inflammation and atherosclerosis. Circulation 105, 1135-1143.
4. Tilley, S. L., Coffman, T. M. and Koller, B. A. (2001) Mixed message gene: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 107, 191-195.
5. Carey, M. A., Germolec, D. R., Langenbach, R. and Zeldin, D. C. (2003) Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot. Essent. Fatty Acids 69, 157-162.
6. 2. Trends Immunol. 25, 40-46.
7. Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. and Willoughby, D. A. (2001) Possible new role for NF-kB in the resolution of inflammation. Nat. Med. 7, 1291-1297.
8. Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zahringer, U., Seydel, U. and Di Padova, F. (1994) Bacterial endotoxin: molecular relationships and structure to activity and function. FASEB J. 8, 217-225.
9. Mararov, S. S. (2000) NF-kB as a therapeutic target in chronic inflammation: recent advances. Mol. Med. Today 6, 441-448.
10. Renard, P. and Raes, M. (1999) The proinflammatory transcription factor NF-kB: a potential target for novel therapeutical strategies. Cell Biol. Toxicol. 15, 341-344.
11. Babbin, B., Laukoetter, M. G., Nava, P., Koch, S., Lee, W. Y., Capaldo, C. T., Peatman, E., Severson, E. A., Flower, R. J., Perretti, M., Parkos, C. A. and Nusrat, A. (2008) Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J. Immunol. 181, 5035-5044.
12. Kamal, A. M., Flower, R. J. and Perretti, M. (2005) An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem. Inst. Oswaldo Cruz. Rio de Janeiro. 100 (Suppl 1), 39-48.
13. Perretti, M. and D'Acquisto, F. (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rew. Immunol. 9, 62-70.
14. Wadia, J. and Dowdy, S. F. (2002) Protein transductiontechnology. Curr. Opin. Biotechnol. 13, 52-56.
15. Ahn, E. H., Kim, D. W., Kang, H. W., Shin, M. J., Won, M. H., Kim, J., Kim, D. J., Kwon, O. S., Kang, T. C., Han, K. H., Park, J., Eum, W. S. and Choi, S. Y. (2010) Transduced PEP-1-ribosomal protein S3 (rpS3) ameliorates 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Toxicol. 276, 192-197.
16. An, J. J., Lee, Y. P., Kim, S. Y., Lee, S. H., Lee, M. J., Jeong, M. S., Kim, D. W., Jang, S. H., Yoo, K. Y., Won, M. H., Kang, T. C., Kwon, O. S., Cho, S. W., Lee, K. S., Park, J., Eum, W. S. and Choi, S. Y. (2008) Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J. 275, 1296-1308.
17. Choi, H. S., An, J. J., Kim, S. Y., Lee, S. H., Kim, D. W., Yoo, K. Y., Won, M. H., Kang, T. C., Kwon, H. J., Kang, J. H., Cho, S. W., Kwon, O. S., Park, J., Eum, W. S. and Choi, S. Y. (2006) PEP-1-SOD fusion protein efficiently protects against paraquat-induced dopaminergic neuron damage in a Parkinson disease mouse model. Free Radic. Biol. Med. 41, 1058-1068.
18. Eum, W. S., Choung, I. S., Li, M. Z., Kang, J. H., Kim, D. W., Park, J., Kwon, H. Y. and Choi, S. Y. (2004) HIV-1 Tat-mediated protein transduction of Cu,Zn-superoxide dismutase into pancreatic β cells in vitro and in vivo. Free Radic. Biol. Med. 37, 339-349.
19. Kim, D. W., Jeong, H. J., Kang, H. W., Shin, M. J., Sohn, E. J., Kim, M. J., Ahn, E. H., An, J. J., Jang, S. H., Yoo, K. Y., Won, M. H., Kang, T. C., Hwang, I. K., Kwon, O. S., Cho, S. W., Park, J., Eum, W. S. and Choi, S. Y. (2009) Transduced PEP-1-catalase fusion protein attenuates ischemic neuronal damage. Free Radic. Biol. Med. 47, 941-952.
20. Lee, S. H., Jeong, H. J., Kim, D. W., Sohn, E. J., Kim, M. J., Kim, D. S., Kang, T. C., Lim, S. S., Kang, I. J., Cho, S. W., Lee, K. S., Park, J., Eum, W. S. and Choi, S. Y. (2010) Enhancement of HIV-1 Tat fusion protein trasnduction efficiency by bog blueberry anthocyanins. BMB Rep. 43, 561-566.
21. Egleton, R. D. and Davis, T. P. (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18, 1431-1439.
22. Dietz, G. P. (2010) Cell-penetrating peptide technology to delivery chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechnol. 11, 167-174.
23. Adams, D. O. and Hamilton, T. A. (1984) The cell biology of macrophage activation. Annu. Rev. Immunol. 2, 283-318.
24. Morrison, D. C. and Ryan, J. L. (1987) Endotoxins and disease mechanisms. Annu. Rev. Med. 38, 417-432.
25. -/- mouse. FASEB J. 17, 253-255.
26. 2 and TNF-α release from human peripheral blood mononuclear cells. Br. J. Pharmacol. 117, 1449-1456.
27. D'Acquisto, F., Cicatiello, L., Iuvone, T., Ialenti, A., Ianaro, A., Esumi, H., Weisz, A. and Carnuccio, R. (1997) Inhibition of inducible nitric oxide synthase gene expression by glucocorticoid-induced proteins in lipopolysaccharide-stimulated J774 cells. Eur. J. Pharmacol. 339, 87-95.
28. Ferlazzo, V., D'agostino, P., Milano, S., Caruso, R., Fes, S., Cillari, E. and Parente, L. (2003) Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthase. Int. Immunopharmacol. 3, 1363-1369.
29. Pieretti, S., Giannuario, A. D., Felice, M. D., Perretti, M. and Cirino, G. (2004) Stimulus-dependent specificity for annexin 1 inhibtion of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides. Pain 109, 52-63.
30. Porro, C. A. and Cavazzuti, M. (1993) Spatial and temporal aspects of spinal cord and brainstem activation in the formalin pain model. Prog. Neurobiol. 41, 565-607.
31. Perretti, M. (1997) Endogenous mediators that inhibit the leukocyote-endothelium interaction. Trends Pharmacol. Sci. 18, 418-425.
32. Cirino, G., Cicala, C., Sorrentino, L., Ciliberto, C., Arpaia, G., Perretti, M. and Flower, R. J. (1993) Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. Br. J. Pharmacol. 108, 573-574.
33. Gayathri, B., Manjula, N., Vinaykumar, K. S., Lakshmi, B. S. and Balakrishnan, A. (2007) Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int. Immunopharmacol. 7, 473-482.
34. Medicherla, S., Ma, J. Y., Reddy, M., Esikova, I., Kerr, I., Movius, F., Higgins, L. S. and Protter, A. A. (2010) Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig. J. Inflamm. Res. 3, 9-16.
35. Lebwohl, M. (2005) A clinician's paradigm in the treatment of psoriasis. J. Am. Acad. Dermatol. 53, 59-69.
36. Barnes, P. J. and Karin, M. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071.
37. 2 production by asiatic acid via NF-kB inactivation in Raw 264.7 macrophages: Possible involvement of the IKK and MAPK pathways. Int. Immunopharmacol. 8, 431-441.
38. Kwon, H. Y., Eum, W. S., Jang, H. W., Kang, J. H., Ryu, J. Y., Lee, B. R., Jin, L. H., Park, J. and Choi, S. Y. (2000) Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett. 485, 163-167.
39. Bradford, M. A. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.